is semaglutide a sglt2 inhibitor once weekly as add-on to SGLT-2 therapy in type 2 diabetes (SUSTAIN 9): randomised, placebo-controlled trial of latest ADA guidelines for

While it may not be drastic, researchers have found that supplementing L-carnitine can help reduce BMI, body weight, and fat mass by a modest amount

Placebo: 2.4% weight reduction with 31.5% of participants achieving at least a 5% weight loss

Wang L, Kounatidis I, Ligoxygakis P

Aside from this lack of difference between the treatment groups, the study had a high dropout rate and, as such, the generalizability of the results of the study should be interpreted with caution

The use of GLP1-RAs represents a potential risk for gallbladder or biliary tract diseases because GLP-1RAs may inhibit gallbladder motility and delay gallbladder emptying by suppressing secretion of cholecystokinin leading to sludging and stone formation